Company

Gamida Cell Ltd.

Headquarters: Jerusalem, Israel

Employees: 166

CEO: Dr. Julian Adams Ph.D.

NASDAQ: GMDA

Market Cap

$42.3 Million

USD as of Jan. 1, 2024

Market Cap History

Gamida Cell Ltd. market capitalization over time

Evolution of Gamida Cell Ltd. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Gamida Cell Ltd.

Detailed Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Gamida Cell Ltd. has the following listings and related stock indices.


Stock: NASDAQ: GMDA wb_incandescent

Details

Headquarters:

5 Nahum Heftsadie Street

Givaat Shaul

Jerusalem, 91340

Israel

Phone: 972 2 659 5666